Coverage of popular obesity drugs like Wegovy and Zepbound will expand to Medicare patients starting next year, with some drugs potentially costing as little as $150. President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy.